Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, ...

Kearney physician Dr. Bradley Rodgers will soon offer Kisunla, the first drug proven to slow the early onset of Alzheimer’s.

The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

Demand for Eli Lilly’s Zepbound and Mounjaro has outstripped supply over the last year, forcing the company to invest heavily ...

The next generation of Alzheimer’s therapeutics is moving away from amyloid plaques and tau tangles, offering multiple ...

Clinical trials need to evolve screening criteria to include diverse patient groups as more Alzheimer's disease drugs become ...

New research suggests certain blood tests could help doctors diagnose Alzheimer's disease faster and more accurately.

The Western New York Chapter of the Alzheimer’s Association will offer a free education program on recognizing and understanding Alzheimer’s disease and dementia at 10 a.m. Thursday at ...

Kisunla (donanemab-azbt) is a brand-name injection for IV infusion prescribed for Alzheimer’s disease. Kisunla has no known interactions with alcohol, other drugs, or supplements. However ...

Kisunla (donanemab-azbt) is a brand-name injection for IV infusion that’s prescribed for certain types of Alzheimer’s disease in adults. As with other drugs, Kisunla can cause side effects ...

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been approved by the U.S. Food and Drug Administration over the past two years. It's ...